Results 161 to 170 of about 24,552 (280)

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

APN Inhibitor Bestatin Induces MM Cell Differentiation Through the CD79B/BTK/STAT3 Pathway. [PDF]

Cells
Wang X, Fang C, Li S, Zeng H, Liu J, Duan X, Zhang X, Jiang W, Wang X.   +8 more
europepmc   +1 more source

Acute Lung Injury: From Molecular Circuits to System‐Level Therapeutics

MedComm, Volume 7, Issue 6, June 2026.
This visual summary illustrates the paradigm shift from linear pathways to network medicine in ALI. Three interconnected circuits—innate immunity, immunometabolism, and cell death (PANoptosis)—drive disease progression under multiorgan crosstalk (gut–lung, brain–lung).
Yaoli Hou, Sheng He, Lili He, Kun Liu, Wen Tang, Deming Wang, Jing Gui, Zhiying Zeng, Yan Wang, Wenjie Liu, Ren Jing   +10 more
wiley   +1 more source

High Complete Responses with Combination of Platinum-Based Regimen with BTK Inhibitors in Richter's Syndrome: University of Miami - Case Series [PDF]

Georgios Pongas, Maryam Alasfour, Deborah Soong, Juan Pablo Alderuccio, Izidore S. Lossos   +4 more
openalex   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures". [PDF]

ACS Pharmacol Transl Sci
Darragh AC, Hanna AM, Lipner JH, King AJ, Servant NB, Jahic M.   +5 more
europepmc   +1 more source

A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia

Yi Xia, haorui shen, Yi Miao, Yuxiao Zhao, Hailing Liu, Sanmei Wang, Tian Tian, Ji Xu, Xiaoyan Qu, Jianyong Li, Lei Fan   +10 more
openalex   +1 more source

348 Differently specific BTK inhibitors impair anti-tumor T-cell immunity [PDF]

Gvantsa Pantsulaia, Judit Svensson‐Arvelund, Moah Sohn, Sidorela Reci, Joshua Brody   +4 more
openalex   +1 more source

Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA) [PDF]

, 2000
Mauno Vihinen
openalex   +1 more source

Peroxisomal Lipid Metabolism as a Therapeutic Target in Leukemia

Molecular Nutrition &Food Research, Volume 70, Issue 11, 15 June 2026.
Peroxisomes are emerging as key regulators of lipid metabolism in leukemia. Enhanced metabolism of very‐long‐chain fatty acids (VLCFAs) supports leukemia cell survival, redox homeostasis, and therapeutic resistance. Pharmacologic disruption of peroxisomal fatty acid oxidation causes VLCFA accumulation, oxidative stress, and mitochondrial dysfunction ...
Ekaterina N. Parfenova, Paul A. Spagnuolo   +1 more
wiley   +1 more source